SecBot SecBot

VRCA

Verrica Pharmaceuticals Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001660334 Biotech & Drug Discovery
$3.42 −0.11 (−3.12%)
Oct 26 4:00 PM ET · prev $3.53
Market cap
$65.8M
Micro cap
Median target
$12.50
+265% · range $9.00–20.00
Next earnings
Nov 9
in 14 days · EPS est. −$0.49
1 year
−9.0%
from $3.76 · Oct 27
30 days
−25.7%
from $4.60
52-week range
$3.28–9.10
−62% from high · low Nov 4
Avg volume 20D
54.8K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$210.9K
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·Next Earnings date, Nov 9, 2026
Strongest BULLISH Verrica Pharmaceuticals announced positive post-hoc data from Phase 3 trials of YCANTH for molluscum…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $210.9K at an average $4.99. No open-market sales. Price is 32% below their cost.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 3 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.427 → −$0.492 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    24% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD279,310$1.7M
Mariner, LLCDOUBLED207,230$1.3M
BlackRock, Inc.ADD74,344$455.0K
JANE STREET GROUP, LLCTRIM23,654$144.8K
RENAISSANCE TECHNOLOGIES LLCTRIM21,769$133.2K
UBS Group AGADD6,071$37.2K
MORGAN STANLEYNEAR_EXIT3,201$19.6K
MARSHALL WACE, LLPADD140,497$743.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2025
12-month targets · 6 analysts

Price is below the lowest target. Median implies +265%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Dec 18, 2025Brookline Capital
UPGRADE
UPGRADEBuy
May 14, 2025Needham
REITERATE
REITERATEHold
Apr 9, 2025Needham
REITERATE
REITERATEHold
Apr 8, 2025HC Wainwright & Co.
REITERATE
REITERATENeutral
Mar 12, 2025Needham
REITERATE
REITERATEHold
Dec 20, 2024Needham
REITERATE
REITERATEHold

Insider ledger

Form 4
$210.9K
bought · 4 insiders
$0
sold · 0 insiders
−31.5%
vs their $4.99 cost
DateInsiderTypeValue
Aug 18, 2026
Rosenberg Noah L.
CMO
BUY$10.0K
Aug 18, 2026
Kirby John J.
Interim CFO
BUY$24.6K
Aug 17, 2026
Zawitz David
Chief Operating Officer
BUY$29.9K
Aug 17, 2026
Rieger Jayson
CEO and President
BUY$24.6K
Aug 17, 2026
Rosenberg Noah L.
CMO
BUY$20.6K
Aug 14, 2026
Rieger Jayson
CEO and President
BUY$101.2K
Jun 5, 2026
Corcoran Gavin
Director
AWARD16,000 sh
Jun 5, 2026
Zawitz David
Chief Operating Officer
AWARD171,340 sh

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.49
EPS estimate, this quarter
−15%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.49-$0.54–-$0.46+5.3%$6.2M
Next Q-$0.45-$0.51–-$0.36+10.8%$7.3M
Current FY-$1.88-$2.03–-$1.70+4.5%$24.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Other
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility
Sep 10, 2026 Press
Verrica Pharmaceuticals announced positive post-hoc data from Phase 3 trials of YCANTH for molluscum contagiosum…
Impact 5/10
Aug 18, 2026 Insider
Rosenberg Noah L. bought 2,030 shares
CMO @ $4.92 ($10.0K)
Aug 18, 2026 Insider
Kirby John J. bought 5,000 shares
Interim CFO @ $4.93 ($24.6K)
Aug 17, 2026 Insider
Zawitz David bought 6,000 shares
Chief Operating Officer @ $4.98 ($29.9K)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
279,310 shares ($1.7M)
Jun 30, 2026 Inst.
Mariner, LLC — DOUBLED
207,230 shares ($1.3M)
Jun 9, 2026 SEC
Verrica Pharmaceuticals filed an 8-K reporting that stockholders approved the Amended and Restated 2018 Equity…
8-K — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
VRCA Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Oct 22, 2026
Press release
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now…
Sep 10, 2026
FDA
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
– Post-hoc analysis shows YCANTH ® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
Aug 6, 2026
Earnings date
VRCA Q2 2026 Earnings Scheduled — 2026-08-06
Jun 22, 2026
Press release
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in…
May 28, 2026
Press release
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and…

SecBot reports

5 filings · 2 press releases · 1 bullish · 1 bearish · 3 neutral
All VRCA filing & press-release reports (7)